Main Article Content


Buccoadhesive tablets of Valsartan were prepared by using Carbopol 934, HPMC K4M and Sodium CMC as mucoadhesive polymers. Nine formulations were developed with varying concentrations of polymers. V1 to V9 formulations were composed of Carbopol 934, HPMC K4M and Sodium CMC in ratios of 1:1, 1:2 and 1:3. The formulated mucoadhesive buccal tablets were assessed for quality attributes like weight variation, hardness, thickness, friability, drug content, moisture absorption, surface pH and in vitro drug release studies. Optimized formulation V4 showed maximum release of the drug (99.72%). The FTIR results showed no evidence of interaction between the drug and polymers. All the evaluation parameters given the positive result and comply with the standards. The results indicated that the mucoadhesive buccal tablets of Valsartan may be good choice to bypass the extensive hepatic first pass metabolism with an improvement in bioavailability of Valsartan through buccal mucosa.


Valsartan Carbopol 934 HPMC K4M Sodium CMC and Buccal tablets

Article Details

How to Cite
Bejawada Sudha, & Ayesha Siddiqua. (2023). Formulation And Evaluation Of Mucoadhesive Buccal Tablets Of Valsartan. International Journal of Research in Pharmacology & Pharmacotherapeutics, 12(4), 253-266. Retrieved from


  1. 1. Iswariya VT, Hari A, Rao OP. Buccal tablets A comprehensive review. ejpmr. 2016;3(8):252-62.
  2. 2. Gupta SK et al. Buccal adhesive drug delivery system: a review. Asian J Biochem Pharm Res. 2011;1(2):105-14.
  3. 3. Sheoran R. Buccal drug delivery system: a review. Int J Pharm Sci Rev Res. May-June 2018;50(1):40-6:Article No. 07.
  4. 4. Wertz PW, Squier CA. Cellular and molecular basis of barrier function in oral epithelium. Crit Rev Ther Drug Carrier Syst. 1991;8(3):237-69. PMID 1954652.
  5. 5. Squier CA, Cox P, Wertz PW. Lipid content and water permeability of skin and oral mucosa. J Invest Dermatol. 1991;96(1):123-6. doi: 10.1111/1523-1747.ep12515931, PMID 1987287.
  6. 6. Squier CA, Wertz PW. Structure and function of the oral mucosa and implications for drug delivery, in Rathbone MJ, Oral Mucosal Drug Delivery, Marcel Dekker, Inc, editors. New York; 1996. p. 1-26.
  7. 7. Galey WR, Lonsdale HK, Nacht S. The in vitro permeability of skin and buccal mucosa to selected drugs and J Pharm Pharmaceut Sci. 1998;1(1):15-30.
  8. 8. Gandhi RB, Robinson JR. Oral cavity as a site for bioadhesive drug delivery. Adv Drug Deliv Rev. 1994;13(1-2):43-74. doi: 10.1016/0169-409X(94)90026-4.
  9. 9. Peppas NA, Buri PA. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Rel. 1985;2:257-75. doi: 10.1016/0168-3659(85)90050-1.
  10. 10. Duchěne D, Touchard F, Peppas NA. A Pharmaceutical and medical aspects of bioadhesive system for drug administration. Drug Dev Ind Pharm. 1988;14(2-3):283-318. doi: 10.3109/03639048809151972.
  11. 11. Patel PS, Parmar AM, Doshi NilangS, Patel HV, Patel RR, Nayee C. Buccal drug delivery system: a review.
  12. 12. Webster’s encyclopedic unabridged dictionary of the English language. Avenel: Thunder Bay Press. NJ; 2001.
  13. 13. Kaelble DH, Moacanin J. A surface energy analysis of bioadhesion. Polymer. 1977;18(5):475-82. doi: 10.1016/0032-3861(77)90164-1.
  14. 14. Gu JM, Robinson JR, Leung S. binding of acrylic polymers to mucin/epithelial surfaces. Structure property-relationship. Crit Rev Ther Drug Car Syst. 1998;5:21-67.
  15. 15. Duchene D, Touchard F, Peppas NA. Pharmaceutical and medical aspects of bioadhesive system for drug administration. Drug Dev Ind Pharm. 1998;14:283-381.
  16. 16. Hollingsbee DA, Timmins P. Topical adhesive system. In: Gurny R, Junginger HE, editors, Wissenchaftliche verlag Gesellschaft, Stuttgart. Bioadhesion possibilities and future trends; 1990. p. 140-64.
  17. 17. Jagadeeshwar Reddy R, Anjum M, Hussain MA. A comprehensive review on buccal drug delivery system. AJADD. 2013;1(3):300-12.
  18. 18. Wise Donald L. Handbook of Pharmaceutical controlled release technology. p. 255-65.